Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 195

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 195
---
 the proprietary rights of third
parties or having third parties circumvent our rights. We have filed and are actively pursuing a patent application for our product candidates.
The patent positions of biotechnology, biopharmaceutical and pharmaceutical companies can be highly uncertain and involve complex legal
and factual questions. Thus, there can be no assurance that our patent application will result in the issuance of a patent, that we will
develop additional proprietary products that are patentable, that any patents issued to us will provide us with any competitive advantages
or will not be challenged by any third parties, that the patents of others will not impede our ability to do business or that third parties
will not be able to circumvent our patents. Furthermore, there can be no assurance that others will not independently develop similar
products, duplicate any of our products not under patent protection, or, if patents are issued to us, design around the patented products
we developed or will develop.

We may be required to obtain
licenses from third parties to avoid infringing patents or other proprietary rights. No assurance can be given that any licenses required
under any such patents or proprietary rights would be made available, if at all, on terms we find acceptable. If we do not obtain such
licenses, we could encounter delays in the introduction of products or could find that the development, manufacture or sale of products
requiring such licenses could be prohibited.

48

A number of pharmaceutical,
biopharmaceutical and biotechnology companies and research and academic institutions have developed technologies, filed patent applications
or received patents on various technologies that may be related to or affect our business. Some of these technologies, applications or
patents may conflict with our technologies or patent applications. Such conflict could limit the scope of the patents, if any, that we
may be able to obtain or result in the denial of our patent applications. In addition, if patents that cover our activities are issued
to other companies, there can be no assurance that we would be able to obtain licenses to these patents at a reasonable cost or be able
to develop or obtain alternative technology. If we do not obtain such licenses, we could encounter delays in the introduction of products,
or could find that the development, manufacture or sale of products requiring such licenses could be prohibited. In addition, we could
incur substantial costs in defending ourselves in suits brought against us on patents it might infringe or in filing suits against others
to have such patents declared invalid.

Much of our know-how and technology
may not be